Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (91-100 of 303) with videos related to

Pageof 31
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community PhysicianAxel Grothey, Gerald Prager, Takayuki Yoshino
The New England Journal of Medicine|July 26, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon CancerQian Shi, James Paul, Axel Grothey
JAMA Oncology|December 23, 2016
Evidence in Favor of Standard Surgical Treatment for Rectal CancerHeidi Nelson, Nikolaos Machairas, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2018
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant TherapiesArvind Dasari, Axel Grothey, Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
The Mechanism of Action of Regorafenib in Colorectal Cancer: Q&AAxel Grothey, Gerald Prager, Takayuki Yoshino
Clinical Colorectal Cancer|June 27, 2006
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancerTara Beers Gibson, Aarati Ranganathan, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon CancerDaniel J Sargent, Thierry André, Axel Grothey
Chinese Clinical Oncology|September 27, 2015
Introduction to special issue on biomarker-based clinical trial designs in oncologyDaniel J Sargent, Sumithra Mandrekar, Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|April 21, 2009
KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitorsHeinz-Josef Lenz, Edward Chu, Axel Grothey
The Lancet. Oncology|July 12, 2016
Adverse event development in clinical oncology trials - Authors' replyGita Thanarajasingam, Jeff A Sloan, Axel Grothey
Pageof 31

Showing results (91-100 of 303) with videos related to

Sort By:
Pageof 31
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
The Mechanism of Action of Regorafenib in Colorectal Cancer: A Guide for the Community PhysicianAxel Grothey, Gerald Prager, Takayuki Yoshino
The New England Journal of Medicine|July 26, 2018
Duration of Adjuvant Chemotherapy for Stage III Colon CancerQian Shi, James Paul, Axel Grothey
JAMA Oncology|December 23, 2016
Evidence in Favor of Standard Surgical Treatment for Rectal CancerHeidi Nelson, Nikolaos Machairas, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2018
Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant TherapiesArvind Dasari, Axel Grothey, Scott Kopetz
Clinical Advances in Hematology & Oncology : H&O|July 29, 2020
The Mechanism of Action of Regorafenib in Colorectal Cancer: Q&AAxel Grothey, Gerald Prager, Takayuki Yoshino
Clinical Colorectal Cancer|June 27, 2006
Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancerTara Beers Gibson, Aarati Ranganathan, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2016
Further Evaluating the Benefit of Adjuvant Chemotherapy for Colon CancerDaniel J Sargent, Thierry André, Axel Grothey
Chinese Clinical Oncology|September 27, 2015
Introduction to special issue on biomarker-based clinical trial designs in oncologyDaniel J Sargent, Sumithra Mandrekar, Axel Grothey
Clinical Advances in Hematology & Oncology : H&O|April 21, 2009
KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitorsHeinz-Josef Lenz, Edward Chu, Axel Grothey
The Lancet. Oncology|July 12, 2016
Adverse event development in clinical oncology trials - Authors' replyGita Thanarajasingam, Jeff A Sloan, Axel Grothey
Pageof 31